> Details

Takahashi, Shin; Fukui, Takafumi; Nomizu, Tadashi; Kakugawa, Yoichiro; Fujishima, Fumisyoshi; Ishida, Takanori; Ohuchi, Noriaki; Ishioka, Chikashi

TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients
  • Contributor: Takahashi, Shin; Fukui, Takafumi; Nomizu, Tadashi; Kakugawa, Yoichiro; Fujishima, Fumisyoshi; Ishida, Takanori; Ohuchi, Noriaki; Ishioka, Chikashi
  • imprint: Springer Science and Business Media LLC, 2021
  • Published in: Breast Cancer
  • Language: English
  • DOI: 10.1007/s12282-021-01250-z
  • ISSN: 1340-6868; 1880-4233
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p><jats:italic>TP53</jats:italic> status based on <jats:italic>TP53</jats:italic> signature, a gene expression profile to determine the presence or absence of <jats:italic>TP53</jats:italic> mutation, is an independent prognostic factor of breast cancer. The purpose of this study was to develop a simple diagnostic system for <jats:italic>TP53</jats:italic> signature status.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We developed a multiplex reverse transcription–polymerase chain reaction system to determine <jats:italic>TP53</jats:italic> status. Based on this system, prospectively collected 189 patients with stage I and II breast cancer were determined to have <jats:italic>TP53</jats:italic> mutant signature or <jats:italic>TP53</jats:italic> wild-type signature. The prognostic significance of the <jats:italic>TP53</jats:italic> signature by the diagnostic system was analyzed.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The diagnostic accuracy of <jats:italic>TP53</jats:italic> status and reproducibility of this diagnosis system was confirmed. Using the diagnostic system, 89 patients were classified as <jats:italic>TP53</jats:italic> mutant signature and the remaining 100 cases were classified as <jats:italic>TP53</jats:italic> wild-type signature. Recurrence-free survival (RFS) among patients with <jats:italic>TP53</jats:italic> mutant signature was significantly shorter than that among those with <jats:italic>TP53</jats:italic> wild-type signature. On univariate and multivariate analyses, the <jats:italic>TP53</jats:italic> signature status was an independent predictor of RFS. RFS among patients with <jats:italic>TP53</jats:italic> mutant signature was significantly shorter than that among those with <jats:italic>TP53</jats:italic> wild-type signature in a cohort of estrogen receptor-positive breast cancer. Although a difference was not significant, no recurrent cases was observed in <jats:italic>TP53</jats:italic> wild-type signature group in triple negative breast cancer.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>This simple and precise diagnostic system to determine <jats:italic>TP53</jats:italic> signature status may help in prognostic assessment, therapeutic decision-making, and treatment optimization in patients with breast cancer.</jats:p> </jats:sec>